Teprotumumab Update: How to introduce Teprotumumab into your practice when it becomes available in your country: focus on patient safety
Author: Steven Leibowitz
Base Hospital / Institution: UCLA Stein Eye Institute
ePoster presentation
Abstract ID: 24-425
Purpose
Present the challenges and potential approaches of starting Teprotumumab at your thyroid eye disease service with a focus on patient safety.
Methods
Presentation of the safety profiles from teprotumumab studies as well as a single provider’s 4-year real-world experience in treating over 250 TED patients. Review of the most current released clinical trial results with respect to balancing broadening indications for the use of teprotumumab versus maintaining patient safety.
Results
There has been over four years of real-world data for the use of teprotumumab. This has provided valuable appreciation of the potential achievable outcomes in clinical practice as well as developing our understanding of contraindications and side effects.
Furthermore, indications for treatment are increasing in line with the clinical trial data for broader range of clinical scenarios, such as for patients with lower activity and severity scores. These will be highlighted with respect to our increasing appreciation of contraindications, side effects and their pre-emptive management strategies.
Conclusion
It is important to be prepared if you are intending to introduce a new treatment into your practice. Teprotumumab is no exception and requires a good appreciation of the clinical indications, clinical trial and real-world outcomes, and contraindications as well as reported side effects. This allows the practitioner and patient to reach a well-balanced informed decision.
Additional Authors
There are no additional authors to display.
